Slide 1: Interim report Q2 2011/12
Interim report Q2 2011/12 By CEO Lars Marcher and CFO Anders Arvai
Slide 2: Agenda
Agenda • Developments in Q2 2011/12 • Status of GPS Four • Outlook for 2011/12
Slide 3: Highlights in Q2 2011/12
Highlights in Q2 2011/12 • Significant improvement in earnings and EBIT margin • The development in the USA is in line with expectations • EMEA is growing, but is negatively impacted by the challenges in Southern Europe • Positive development in Asia – continued strengthening of growth platform • Ca
Slide 4: Growth in EBIT and profit
Growth in EBIT and profit Revenue EBIT, DKKm Net profit for the period, DKKm • Revenue in Q2 2011/12 of • Gross margin ratio up at • Net financials constitute DKK 265m, corresponding 56.0% from 54.8% in the expenses of DKK 0.1m to an increase of 4%, or 2% same period last year against DKK 3.2m last
Slide 5: Development – markets
Development – markets USA, DKKm Europe, DKKm Rest of the world, DKKm • Revenue growth of 2% • Growth in revenue of 1% • Growth in revenue in the in local currencies and and year to date rest of the world of 11% 6% in Danish kroner unchanged and 7% year to date (DKK). Growth in H1 of • Variation in g
Slide 6: Development – business areas
Development – business areas Anesthesia, DKKm Patient Mon. & Diagnostics, DKKm Emergency Care, DKKm • Fall in revenue of 1% in • Revenue growth of 6% • Fall in revenue of 3% in local currencies. Revenue in local currencies in Q1 local currencies and 2% in in H1 unchanged. and 4% year to date Danish
Slide 7: Continued positive expectations for aScope
Continued positive expectations for aScope • Growing interest in and recognition of aScope • Sales of aScope continue to grow, although penetration takes longer than originally anticipated – old habits die hard • aScope is still expected to hold a highly attractive potential • It takes time to get u
Slide 8: Cash flow
Cash flow DKKm H1 2010/11 H1 2011/12 Cash flow from operating activities 38.8 14.2 Cash flow from investing activities, including (12.8) (19.7) acquisitions Free cash flow 26.0 (5.4) Cash flow from financing activities (18.3) 10.0 • Cash flow from operating activities negatively affected by increasi
Slide 9: GPS Four – Status of Ambu's business strategy
GPS Four Status of Ambu’s business strategy
Slide 10: GPS Four – overview
GPS Four — overview PLATFORM DEVELOPMENT 2009-2010 Establishment of sales regions Establishment of global innovation organisation Implementation of global IT systems Moving of remaining production in Denmark to Asia initiated Expansion of factory in China Ambu™ Idews thet work for © COST OPTIMISATIO
Slide 11: Update on activities in Q2 associated with the GPS Four strategy
Update on activities in Q2 associated with the GPS Four strategy • The products SmartInfuser™ Pain Pump and SmartBlock™ launched in the US market at the end of Q1 2011/12 – well received. • Product development: Work is going into developing two important new visualisation products – is progressing a
Slide 12: Outlook 2011/12
Outlook 2011/12
Slide 13: Outlook for 2011/12
Outlook for 2011/12 2011/12 Comments Revenue In the region of DKK 1,025- Increased revenue in emerging markets and 1,035m success with new products Growth When measured in Danish kroner and local Approx. 5% currencies Increased market share Formation of partnerships USD exchange rate: 540 GBP exchan
Slide 14: Growth initiatives
Growth initiatives Growth initiatives within sales, investments in emerging markets, innovation and acquisitions •Focus on organic growth in the USA and EMEA, driven, among other things, by an increased number of outside and inside salespeople in the USA, focused sales efforts in EMEA and revenue gr
Slide 15: Questions
a \. q " - "| “. is >= . ‘ <*, 4 Ms, hs i 7 — SS <3 Ambu? ’. oe. R&S s that work for life AA & cs Questions
Slide 16: For further information, please contact
READ MORE AT WWW.AMBU.COM For further information, please contact: CEO Lars Marcher, lm@ambu.com or +45 5136 2490 CFO Anders Arvai, aa@ambu.com or +45 7225 2000